Generation of T Regulatory Cells in Children with Newly Diagnosed Type 1 Diabetes Mellitus

Abstract

There is increasing evidence that T-regulatory (Treg) cells could be used to prevent or cure autoimmune diseases including type 1 diabetes mellitus (T1DM). The aim of the present study was to verify the hypothesis that functional Treg cells can be generated from conventional T-cells separated from a small amount of peripheral blood of children with newly diagnosed T1DM (N=25).

Methods:

CD4⁺CD25^- cells were cultured with Treg expander (CD3/CD28) and IL-2 for generating de novo Treg cells. The assessment of the expression of selected genes and proteins critical to Treg function and the proliferation assays were performed with the use of real-time RT-PCR and flow cytometry.

Results:

After a 4-week stimulation with Treg expander and IL-2, the percentage of T-regulatory cells was significantly higher compared to the cells treated with medium alone (with no difference between diabetic and control children). However, we found some disturbances in the gene expression at mRNA level for molecules crucial for T-reg function. The induced Tregs from diabetic and control children were fully functional as assessed in proliferation assays.

In summary:

despite some disturbances at mRNA level in the critical gene expression, the suppressive properties of induced Treg cells from diabetic and control children were effective.

Key words

T regulatory cell - diabetes - children - immunotherapy - mRNA

• References

• 1 Alam MS, Kurtz CC, Rowlett RM et al. CD73 is expressed by human regulatory T helper cells ans suppresses proinflammatory cytokine production and Helicobacter felis-induced gastritis in mice. J Infect Dis 2009; 199: 494-504
• 2 Bardel E, Larousserie F, Charlot-Rabiega P et al. Human CD4+ CD25+ FoxP3+ regulatory T cells do not constitutively express IL-35. J Immunol 2008; 181: 6898-6905
• 3 Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010; 464: 1293-1300
• 4 Bluestone JA, Tang Q, Sedwick CE. T regulatory cells in autoimmune diabetes: past challenges, future prospects. J Clin Immunol 2008; 28: 677-684
• 5 Bour-Jordan H, Bluestone JA. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev 2009; 229: 41-66
• 6 Brusko T, Wasserfall C, McGrail K et al. No alterations in the frequency of FoxP3+ regulatory T-cells in type 1 diabetes. Diabetes 2007; 56: 604-612
• 7 Brusko TM, Wasserfall CH, Clare-Salzler MJ et al. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 2005; 54: 1407-1414
• 8 Camisaschi C, Casati C, Rini F et al. LAG-3 expression defines a subset of CD4+CD25highFoxP3+ regulatory T cells that are expanded at tumor sites. J Immunol 2010; 184: 6545-6551
• 9 Cao Z, Wara AK, Icli B et al. Kruppel-like Factor KLF10 targets transforming growth factor-beta1 to regulate CD4+CD25− T cells and T regulatory cells. J Biol Chem 2009; 284: 24914-24924
• 10 Collison LW, Chaturvedi V, Henderson AL et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010; 11: 1093-1101
• 11 Dwyer KM, Hanidziar D, Putheti P et al. Expression of CD39 by human peripheral blood CD4+CD25+ T cells denotes a regulatory memory phenotype. Am J Transplant 2010; 10: 2410-2420
• 12 Feuerer M, Hill JA, Kretschmer K et al. Genomic definition of multiple ex vivo regulatory T cell subphenotypes. Proc Natl Acad Sci 2010; 107: 5919-5924
• 13 Glisic S, Ehlenbach S, Jailwala P et al. Inducible regulatory T cells (iTregs) from recent onset type 1 diabetes subjects show increased in vitro suppression and higher ITCH levels compared with controls. Cell Tiss Res 2010; 339: 585-595
• 14 Grinberg-Bleyer Y, Baeyens A, You S et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 2010; 207: 1871-1878
• 15 Jaeckel E, Mpofu N, Saal N et al. Role of regulatory T cells for the treatment of type 1 diabetes mellitus. Horm Metab Res 2008; 40: 126-136
• 16 Jarosz-Chobot P, Deja G, Polanska J. Epidemiology of type 1 diabetes among Silesian children aged 0–14 years, 1989–2005. Acta Diabetol 2010; 47: 29-33
• 17 Kmieciak M, Gowda M, Graham L et al. Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function. J Transl Med 2009; 7: 89
• 18 Kukreja A, Cost G, Marker J et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002; 109: 131-140
• 19 Langhans B, Braunschweiger I, Arndt S et al. Core-specific adaptive regulatory T-cells in different outcomes of hepatitis C. Clin Sci (Lond) 2010; 119: 97-109
• 20 Layland LE, Mages J, Loddenkemper C et al. Pronounced phenotype in activated regulatory T cells during a chronic helminth infection. J Immunol 2010; 184: 713-724
• 21 Lin AE, Mak TW. The role of E3 ligases in autoimmunity and the regulation of autoreactive T cells. Curr Opin Immunol 2007; 19: 665-673
• 22 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ddCT method. Methods 2001; 25: 402-408
• 23 Longhi MS, Meda F, Wang P et al. Expansion and de novo generation of potentiatlly therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 2008; 47: 581-591
• 24 Luczynski W, Wawrusiewicz-Kurylonek N, Stasiak-Barmuta A et al. Diminished expression of ICOS, GITR and CTLA-4 at the mRNA level in T regulatory cells of children with newly diagnosed type 1 diabetes. Acta Biochim Pol 2009; 56: 361-370
• 25 Luo X, Herold KC, Miller SD. Immunotherapy of type 1 diabetes: where are we and where should we be going?. Immunity 2010; 32: 488-499
• 26 Milpied P, Renand A, Bruneau J et al. Neuropilin-1 is not a marker of human FoxP3+ Tregs. Eur J Immunol 2009; 39: 1466-1471
• 27 Oberg HH, Wesch D, Grussel S et al. Differential expression of CD126 and CD130 mediated different STAT-3 phosphorylation in CD4+CD25- and CD25high regulatory T cells. Int Immunol 2006; 18: 555-563
• 28 Orban T, Farkas K, Jalahej H et al. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 2010; 34: 4
• 29 Perone MJ, Bertera S, Shufesky WJ et al. Suppression of autoimmune diabetes by soluble galectin-1. J Immunol 2009; 182: 2641-2653
• 30 Probst-Kepper M, Geffers R, Kroger A et al. GARP: a key receptor controlling FOXP3 in human regulatory T cells. J Cell Mol Med 2009; 13: 3343-3357
• 31 Rao PE, Petrone AL, Ponath PD. Differentiation and expansion of T cells with regulatory function from human peripheral lymphocytes by stimulation in the presence of TGF-beta. J Immunol 2005; 174: 1446-1455
• 32 Sakaguchi S, Yamaguchi T, Nomura T et al. Regulatory T cells and immune tolerance. Cell 2008; 133: 775-787
• 33 Sgouroudis E, Piccirillo CA. Control of type 1 diabetes by CD4+Foxp3+ regulatory T cells: lessons from mouse models and implications for human disease. Diabetes Metab Res Rev 2009; 25: 208-218
• 34 Shevach EM. Mechanisms of FoxP3+ T regulatory cell-mediated suppression. Immunity 2009; 30: 636-645
• 35 So T, Lee SW, Croft M. Immune regulation and control of regulatory T cells by OX40 and 4-1BB. Cytokine Growth Factor Rev 2008; 19: 253-262
• 36 Sojka DK, Huang YH, Fowell DJ. Mechanisms of regulatory T-cell suppression – a diverse arsenal for a moving target. Immunology 2008; 124: 13-22
• 37 Stockis J, Colau D, Coulie PG et al. Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur J Immunol 2009; 39: 3315-3322
• 38 Stroopinsky D, Avivi I, Rowe JM et al. Allogeneic induced human FOXP3(+)IFN-gamma(+) T cells exhibit selective suppressive capacity. Eur J Immunol 2009; 39: 2703-2715
• 39 Su J, Liu YC. Foxp3 positive regulatory T cells: a functional regulation by the E3 ubiquitin ligase Itch. Semin Immunopathol 2010; 32: 149-156
• 40 Sugimoto N, Oida T, Hirota K et al. FoxP3-dependent and -independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis. Int Immunol 2006; 18: 1197-1209
• 41 Tran DQ, Andersson J, Wang R et al. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FoxP3+ regulatory T cells. Proc Natl Acad Sci 2009; 106: 13445-13450
• 42 Uhlig HH, Coombes J, Mottet C et al. Characterization of FoxP3+CD4+CD25+ and IL-10 secreting CD4+CD25+ T cells during cure of colitis. J Immunol 2006; 177: 5852-5860
• 43 Venuprasad K, Huang H, Harada Y et al. The E3 ubiquitin ligase Itch regulates expression of transcription factor Foxp3 and airway inflammation by enhancing the function of transcription factor TIEG1. Nat Immunol 2008; 9: 245-253
• 44 Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008; 8: 523-532
• 45 Wang R, Kozhaya L, Mercer F et al. Expression of GARP selectively identifies activated human FoxP3+regulated T cells. PNAS 2009; 106: 13439-13444
• 46 Zaccone P, Burton O, Miller N et al. Schistosoma mansoni egg antigens induce Treg that participate in diabetes prevention in NOD mice. Eur J Immunol 2009; 39: 1098-1107
• 47 Zhou X, Bailey-Bucktrout S, Jeker LT et al. Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol 2009; 21: 281-285